The abstract is read at the publisher; the summary is JClub's.
In 254 polycythemia vera patients on second-line ruxolitinib, European LeukemiaNet clinical signs and symptoms predict higher thrombosis and progression rates, with progression linked to persistent leukocytosis.
- Why it matters: Conventional thrombotic risk categories do not clarify prognosis during ruxolitinib, leaving uncertainty about whether baseline clinical signs and symptoms forecast thrombosis or progression to secondary myelofibrosis or acute leukemia.
- What they did: Using the PV-ARC multicenter cohort, investigators calculated incidence rate ratios for thrombosis and SMF/AL during ruxolitinib and tested whether European LeukemiaNet CSSs at treatment initiation predicted outcomes.
- The result: CSSs were present in 50.4% of patients and were associated with higher thrombosis IRRs (1.8 vs 0 %p–y, p=0.05) and progression IRRs (6.0 vs 2.3 %p–y, p=0.02), while persistent or progressive leukocytosis was the strongest predictor of progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.